Related Experiment Videos
Cdc25 as a potential target of anticancer agents
1Enanta Pharmaceuticals, Cambridge, MA 02139, USA. eckstein@enanta.com
Abstract:
Ever since its discovery in yeast more than a decade ago [1], Cdc25 has continued to surprise and intrigue researchers. This dual-specificity protein tyrosine phosphatase (dsPTPase) and other members of the protein tyrosine phosphatase family (PTPases) have only recently joined the protease and kinase enzyme families in drug discovery efforts. The role of phosphatases in tumourigenesis was reviewed recently by Parsons [2]. He is arguing that the phosphatase family of enzymes is involved in a variety of cancers and thus poses both a challenge and an opportunity for new therapeutics. The general biology and biochemistry of Cdc25 were recently reviewed [3]. Here I shall first summarize the recent literature on the role of Cdc25 in disease, as well as on new insights into the regulation of this family of proteins. In the second part, I will review current knowledge of the Cdc25 protein structure and the chemical structures and activities of published Cdc25 inhibitors.
Insights
Cdc25 phosphatases are crucial in cancer, presenting therapeutic opportunities. Research explores Cdc25
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cdc25 phosphatases, a family of dual-specificity protein tyrosine phosphatases (dsPTPases), play a significant role in cellular regulation.
- Dysregulation of phosphatases, including Cdc25, is implicated in various cancers, highlighting their potential as therapeutic targets.
- Recent research has focused on understanding the biology, biochemistry, and regulatory mechanisms of the Cdc25 family.
Purpose of the Study:
- To summarize recent findings on the role of Cdc25 in disease pathogenesis.
- To review novel insights into the regulation of Cdc25 protein family.
- To present current knowledge on Cdc25 protein structure and inhibitors for drug discovery.
Main Methods:
- Literature review of recent studies on Cdc25's role in disease.
- Analysis of new findings regarding Cdc25 regulation.
- Compilation of data on Cdc25 protein structure and inhibitor chemical structures/activities.
Main Results:
- Cdc25 phosphatases are increasingly recognized for their involvement in tumorigenesis.
- New regulatory mechanisms for Cdc25 have been elucidated.
- A growing number of Cdc25 inhibitors with diverse chemical structures and activities have been reported.
Conclusions:
- Cdc25 phosphatases represent a promising target class for cancer therapeutics.
- Further research into Cdc25 structure and inhibition is crucial for developing effective drugs.
- Understanding Cdc25 regulation is key to exploiting its therapeutic potential in oncology.